|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO008333769 |
| 003 |
DE-627 |
| 005 |
20230425170619.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
220420s2021 xx |||||o 00| ||und c |
| 035 |
|
|
|a (DE-627)WHO008333769
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2021-002171-19-AT
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)HEVACC
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a und
|
| 245 |
1 |
0 |
|a Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost
|b Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 27-04-2021, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Immunization for SARS-CoV-2 MedDRA version: 20.0Level: LLTClassification code 10021433Term: ImmunizationSystem Organ Class: 100000004865;Therapeutic area: Not possible to specify
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 08. Okt.
|
| 773 |
1 |
8 |
|g year:2021
|g day:08
|g month:10
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-002171-19
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2021
|b 08
|c 10
|
Klinische Studie